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Abstract
Background:  Gynecological laparoscopic surgery procedures are often complicated by
postoperative pain resulting in an unpleasant experience for the patient, delayed discharge, and
increased cost. Glucocorticosteroids have been suggested to reduce the severity and incidence of
postoperative pain.
Methods: This study examines the efficacy of a sustained release betamethasone preparation to
reduce postoperative pain and the requirement for pain relief drugs after either diagnostic
laparoscopy or tubal ligation. Patients were recruited, as presenting, after obtaining informed
consent. Prior to surgery, patients were randomly selected by a computer generated table to
receive either pharmacy-coded betamethasone (12 mg IM Celestone™) or an optically identical
placebo injection of Intralipid™ and isotonic saline mixture. The effect of non-controlled
prophylactic intraoperative treatment with either fentanyl or ketorolac per surgeon's orders was
also noted in this study. Blood samples taken at recovery and at discharge times were extracted
and analyzed for circulating betamethasone. Visual analog scale data on pain was gathered at six
post-recovery time points in a triple blind fashion and statistically compared. The postoperative
requirement for pain relief drugs was also examined.
Results: Although the injection achieved a sustained therapeutic concentration, no beneficial effect
of IM betamethasone on postoperative pain or reduction in pain relief drugs was observed during
the postoperative period. Indeed, the mean combined pain scores during the 2 hour postoperative
period, adjusted for postoperative opioids as the major confounding factor, were higher
approaching statistical significance (P = 0.056) in the treatment group. Higher pain scores were also
observed for the tubal ligation patients relative to diagnostic laparoscopy. Intraoperative fentanyl
treatment did not significantly lower the average pain score during the 2 hour postoperative period.
Intraoperative ketorolac treatment significantly lowered (P = 0.027) pain scores and reduced the
postoperative requirement for additional pain relief drugs.
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Conclusions: There was a lack of efficacy of preoperative sustained release betamethasone in
reducing postoperative pain despite maintaining a therapeutic concentration during the
postoperative period. Intraoperative Ketorolac did afford some short-term pain relief in the
postoperative period and reduced the need for additional pain relief drugs.
Background
Laparoscopic procedures are often complicated by post-
operative pain symptoms [1]. Manufactured derivatives of
glucocorticoids such as betamethasone or dexamethasone
are 25–30 fold more potent by weight than endogenous
cortisol in terms of anti-inflammatory activity [2]. These
compounds have been used to ameliorate postoperative
pain symptoms in oral and laparoscopic surgeries [3,4]
presumably by attenuation of lipid inflammatory media-
tors thought to have a role in postoperative pain [4]. More
recently the effectiveness of glucocorticoids has been
questioned in pediatric tonsillectomy [5], laparoscopic
cholecystectomy [6] and inguinal herniorrhaphy with spi-
nal anesthesia [7]. Celestone Soluspan is an injectable
combination of fast acting and prolonged effect betame-
thasone. IM injection of 12 mg of Celestone has been
reported to be efficacious in management of pain after
ambulatory surgery, perhaps by delivering a longer lasting
dose [4]. Since this prophylactic treatment is relatively
safe and inexpensive, the current study was designed to
test whether preoperative administration of this form of
betamethasone would alleviate postoperative pain in
women undergoing either tubal ligation or diagnostic
laparoscopic procedures. In addition the intraoperative
administration of either a prophylactic non-steroidal anti-
inflammatory or an opioid per surgeons orders was eval-
uated along with the type of procedure.
Methods
Betamethasone was obtained from Schering-Plough Phar-
maceuticals as an injectable 50% betamethasone di-
sodium-phosphate (fast onset): 50% betamethasone ace-
tate (slower onset and long acting) suspension (Celestone
Soluspan™). Intralipid™, obtained from Kabivitrum Inc, is
an aqueous suspension of lipid droplets that is sterile,
suitable for intravenous feeding of patients and thus safe
for IM injection [4]. Intralipid™ mixed with sterile isot-
onic saline was used to prepare a visually identical coded
placebo injection prepared by the pharmacist. Pharmacy
coded injections were provided to the anesthesiologist
who along with the patient, surgeon and persons collect-
ing postoperative data were blinded as to the contents.
Patients (N total of 74), as presenting, and after giving
Institutional Review Board approved written informed
consent conforming to the Helsinki II declaration, were
randomly assigned by a computer generated table to bet-
amethasone treatment (BM) or placebo (P) groups. Eight
patients were later excluded from further data collection
when their surgery evolved from a laparoscopic into an
open procedure, leaving a total of 66 patients evaluated
for postoperative pain after either diagnostic laparoscopy
(N = 37) or tubal ligation (N = 29). Prior to surgery,
patients were assessed for preoperative pain. In this dou-
ble blind and placebo controlled study the P group (N =
35) received a coded placebo injection of Intralipid™
mixed with sterile isotonic saline while the BM treatment
group (N = 31) received a coded injection of 12 mg Cele-
stone Soluspan™ IM (gluteal muscle) 30–60 minutes prior
to surgery. Patients were pre-medicated with 2 mg versed
and anesthesia was induced with 1.5 mg kg-1 lidocaine, 3
mg curare, 2.5 µg kg-1 fentanyl, 2.5 mg kg-1 propofol, and
1.5 mg kg-1 succinylcholine. Anesthesia was maintained
with isoflurane in 65% nitrous oxide : 35 % oxygen, with
muscle relaxation achieved with vecuronium if needed.
Intraoperative analgesics, either an additional IV bolus of
2.5 µg kg-1 fentanyl or 30 mg ketorolac (ketorolac tromet-
amol) administered at the end of the procedure, were
given to some of the patients per surgeon's instructions
and noted as part of this study.
Pain was assessed using the position of the patient's mark
on a 100 mm visual analog scale (VAS), with 0 = none and
100 = worst possible pain, at 15, 30, 60, and 120 minutes
post operation. In all cases the interviewer was blinded as
to the treatment. The type and amount of postoperative
pain relief drugs from recovery till discharge was also
noted.
Blood samples were taken by standard phlebotomy tech-
niques upon recovery and at discharge. Serum samples
were obtained by centrifugation and frozen at -70°C until
extraction and analysis by high performance liquid chro-
matography. Sera (0.5–1.0 ml) were twice extracted with
3 volumes of ether with collection of the ether phase. The
solvent was evaporated at 40–45°C under a gentle stream
of nitrogen and the residue dissolved in 0.1 ml of water-
acetonitrile (60:40, v/v, acidified to pH 3.45 with acetic
acid) and centrifuged to remove insoluble material. Aliq-
uots of 25 µL were analyzed on a Waters Symmetry-C18,
3.5 micron, 4.6 mm × 15 cm column using a Waters HPLC
pump (Model 470) and WISP (Model 710B) autoinjector.
Monitoring of the chromatograms was done with UV
detection at 254 nanometersm. Standards of betametha-
sone were run to establish calibration curves that wereBMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/3
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used to convert peak areas from patient samples to nano-
grams ml-1.
Two-sided statistical comparisons were done with
StatView v4.5 (Abacus Concepts, Inc., CA, USA) computer
program and SPSS version 10.0 (SPSS Inc., IL, USA). The
groups were tested for differences using Student's
unpaired and paired t-tests for continuous variables and
Chi-Square for categorical variables. Repeated measures
ANOVA with Huynh-Feldt correction was used to analyze
multiple within-group comparisons, within subject effect
of survey time, and the interaction between time and
treatment. Regression analysis was used to determine the
effect of the analgesics controlling for the other factors. All
data were evaluated for normality of distribution, equality
of variances, and other assumptions. If necessary, data
were either log transformed to achieve a normal distribu-
tion or nonparametric tests were used. A P value of less
than 0.05 was used to determine statistical significance.
Results
Eight patients, selected with the intention to treat, were
excluded from the analysis when the laparoscopic proce-
dure evolved into a open procedure. This resulted in a loss
of 2 patients from the P group and 6 patients from the BM
group. The remaining patient group characteristics are
given in Table 1. The groups were well matched with
respect to age, body mass index (BMI), surgery duration,
time until recovery from anesthesia, and time until dis-
charge from the hospital. The groups were also closely
matched in the number of subjects classified as ASA II
health status (54% P group, 45% in the BM group), post-
menopausal status (11% P group, 16% BM group), and
subjects experiencing preoperative pain (26% P group,
29% BM group). The number of tubal ligations and diag-
nostic laparoscopy procedure were also evenly distributed
between groups (48% tubal ligation in the BM group and
40% in the P group). Extra analgesics administered at the
end of the surgery, per surgeon's orders, consisted of
ketorolac (8 in the P group, 9 in the BM group) or fentanyl
(10 in the P group, 8 in the BM group).
As shown in Figure 1, pain scores for the BM treatment
group were higher at all postoperative time points and
reached statistical significance (P < 0.05, power > 0.8) by
repeated measures ANOVA) at the 60 and 120 minutes
survey times. To determine that this formulation of beta-
methasone given IM achieved a sustained circulating con-
centration, we sampled blood at recovery and upon
discharge and analyzed every other patient sample in the
BM treatment group. A stable serum concentration was
obtained with no significant difference in betamethasone
concentrations (P = 0.95 by paired t-testing) between the
recovery (70 ± 12 nanograms ml-1 mean ± S.E.M.) and dis-
charge (71 ± 8 nanograms ml-1) sera from the same
patient. There was also no significant difference in mean
betamethasone concentrations between obese and nor-
mal weight patients in this group at either time point. This
data were also evaluated by examining the influence of
weight. There was no significant Spearman Rank correla-
tion between the patient's weight and betamethasone
concentrations at either sampling time (P = 0.59 at recov-
ery, P = 0.25 at discharge).
Although not a controlled part of this study, fentanyl or
ketorolac were given at the end of the intraoperative time
for a considerable number of patients in the study. The
effect of these treatments was also evaluated independ-
ently of the betamethasone treatment (which had no sig-
nificant effect on the other treatments, P values all > 0.05).
The treatment with fentanyl had no significant effect (P
values all > 0.05) on pain at any of the time points with
the greatest difference observed at 120 minutes after sur-
gery (fentanyl pain VAS 19 ± 4, versus 29 ± 4, mean ±
S.E.M., P = 0.15). Shown in figure 2, are the pain scores for
the ketorolac treated patients, compared to the rest, with-
out regard for betamethasone treatment. Ketorolac did
significantly lower pain scores at the 15 minute survey
time and pain scores were lower through the 60 minute
postoperative time but not at later time points. Also signif-
icantly correlated (P = 0.016) was a lower requirement
(76% versus 96%) for additional pain drugs in the recov-
ery to discharge period, which was not observed for the
intraoperative fentanyl treatment (94% versus 90%, P =
0.54). However, ketorolac did not significantly shorten
the time from recovery to discharge (treated 178 ± 10,
other 192 ± 11, mean minutes ± S.E.M., P = 0.49).
The type of surgery was associated with a significant differ-
ence in preoperative pain (slightly greater for the diagnos-
tic laparoscopy group, P = 0.023) and in postoperative
pain experienced at 60 minutes after surgery (greater for
the tubal ligation group, P = 0.018) as shown in Figure 3.
The average surgery time for tubal ligation was not
significantly shorter (73.9 ± 9.3 versus diagnostic laparos-
copy 96.8 ± 8.0 minutes ± S.E.M., P = 0.07, unpaired T-
Test). Recovery times and time to discharge were also sim-
ilar and not significant (P > 0.34). Tubal ligation was asso-
ciated with higher pain levels through the discharge time
point and was not reduced by betamethasone or by intra-
operative fentanyl. Ketorolac did provide significant pain
relief at 15 minutes after either tubal ligation surgery (P =
0.028) or diagnostic laparoscopy (P = 0.024), but not at
later time points.
Only 6 patients did not require additional pain drugs in
the postoperative period until discharge and significantly
(Fisher Exact Test P = 0.026) all of these were in the pla-
cebo group. In the first 1 hour time period 80% of the
patients received at least one dose of an opioid (48% – 25BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/3
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µg fentanyl IV, 21% – 2 mg morphine IV, 5% – 12.5 mg
Demerol IV, 1 patient – 0.6 mg Dilaudid IV, 23% – 1 tab-
let Percocet PO) for pain relief. A single dose of 30 mg
ketorolac was also given to 17 patients, 2 also receiving
intraoperative ketorolac. For statistical analysis the total
doses of pain medications were summed for the entire
recovery to discharge time period. The number of doses,
normally distributed with a only slight positive skewness,
had a mean of 5.2 ± 0.4 S.E.M. and a median number of 5
doses of pain medications (range of 0–17 doses).
Regression analysis was used to study which factors influ-
enced the mean of the postoperative pain scores during
the first two hours. The measures included preoperative
pain, betamethasone treatment, intraoperative ketorolac,
and the number of opioid doses. Two-way interactions of
those factors were also examined to verify that the differ-
ent groups had equal slopes between the covariates and
postoperative pain. Preoperative pain, which had poten-
tial as a covariate, showed no relationship with postoper-
ative pain since the great majority of subjects had no
preoperative pain. The most significant factor was number
of postoperative opioid doses (P < 0.001), followed by
intraoperative ketorolac treatment (P < 0.025), see Table
2. After correcting for the postoperative opioid doses and
intraoperative ketorolac administration, the effect of bet-
amethasone treatment was not quite significant at P  =
0.056. These combined factors were able to account for
39% of the variance in the post-operative pain scores.
Discussion
This study indicates that the betamethasone, Celestone
Soluspan, administered IM is not an effective treatment
for gynecological laparoscopic postoperative pain.
Indeed, higher pain scores were reported in the postoper-
ative time period by the BM treatment group. One possi-
ble mechanism for this increase might be a reduction in
plasma beta-endorphins which might increase pain per-
ception. This has been reported after surgical extraction of
impacted teeth in subjects pretreated with a closely related
glucocorticoid, dexamethasone [8]. In contrast to our
results, a previous study [4] reported that 12 mg slow and
fast acting IM betamethasone significantly reduced post-
operative pain by 50% in patients undergoing ambulatory
hemorrhoidectomy or hallux valgus correction surgery.
These significant beneficial effects were not observed at
the 1 hour postoperative time point, but were observed at
2, 3, and 4 hours. In our study the median postoperative
time to discharge was 166 minutes (P) and 177 minutes
(BM). This suggests that the type of procedure and dura-
tion of recovery time may be important considerations for
Celestone Soluspan's therapeutic results. The average
body mass index in the previous study using Celestone
Soluspan at 12 mg IM (BMI = 23 ± 6 Std. Dev.) in a Nor-
wegian population [4] was lower than the BMI = 27 ± 6 for
the American treatment group in this study. We analyzed
the data to determine if greater BMI or weight may reduce
the systemic circulating concentration of betamethasone,
but found no significant difference between obese and
normal weight groups. The mean circulating serum con-
centration for betamethasone determined in this study
was 70 at recovery and 71 nanograms ml-1 at discharge, an
average of 3 hours later. This is comparable to the 83 –
115 nanograms ml-1 peak plasma concentration at 10 – 36
minutes with a clearance half time of 5 – 6 hours after a
therapeutic IV dose of 10.6 mg [9].
We also evaluated prophylactic intraoperative administra-
tion of either fentanyl or ketorolac administered per sur-
geon's orders. In agreement with previous studies [10,11]
we found ketorolac did provide short-term pain relief in
the postoperative period up to 120 minutes and signifi-
Table 1: Patient Characteristics
Parameter Group P (N = 35)
BM (N = 31)
Median Minimum Maximum Variance
Age (years) P 29 21 49 65
BM 30 21 46 44
BMI (kg m-2)P 28.6 19.8 39.1 25.9
BM 27.0 19.3 45.0 38.0
Surgery time 
(minutes)
P 67 38 214 2891
BM 75 32 291 2196
Recovery time 
(minutes)
P 81 37 215 1305
BM 97 38 222 1385
To discharge time 
(minutes)
P 1 6 81 1 43 4 73 1 9 5
BM 1 7 51 0 84 3 86 3 6 1BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/3
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cantly reduced the need for postoperative pain relief
drugs. However, we did not find the reported [10] differ-
ence in effectiveness of ketorolac between diagnostic
laparoscopy and tubal ligation. Prophylactic intraopera-
tive fentanyl had no significant effect on postoperative
pain scores or drug requirements. However, a major con-
founding factor in this study is the prevalence of opioid
doses given in the 2 hour postoperative period which has
a highly significant effect on the average pain scores.
The type of surgery and timing of preemptive analgesia for
postoperative pain has recently been reviewed as a litera-
ture analysis [12] with the conclusion that current
approaches are ineffective and more aggressive
preemptive treatments are indicated. The definition of a
clinically significant reduction in pain was also addressed
in this review. Pain scores on a 0–100 mm VAS were asso-
ciated with a verbal rating of no (0), light (25), moderate
(50) and severe (75). Studies with control group postop-
erative scores < 30 mm were considered less significant
since a preemptive treatment reduction would be difficult
Plotted are the mean (+ S.E.M. error bar) visual analog scores (VAS) for pain using a patient-marked 100 mm line with 0 = no  pain and 100 = worst pain Figure 1
Plotted are the mean (+ S.E.M. error bar) visual analog scores (VAS) for pain using a patient-marked 100 mm line with 0 = no 
pain and 100 = worst pain. Repeated measures ANOVA as indicated for the P group (shaded bar) and BM group (solid bar). 
Number of subjects interviewed at each time point is indicated above each set of bars. Number lower than enrolled reflects 
unresponsive subjects at early postoperative times and subjects discharged early for later time points. Repeated measures 
ANOVA showed a significant within subject effect of time (F = 7.9921 (with Huynh-Feldt correction) ; P = 0.02) but the inter-
action between time and treatment were not significant (F = 0.453; P = 0.84).
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to detect. In this study, immediate postoperative pain
scores were generally in the moderate range (50–75) with
only intra-operative ketorolac reducing pain in the first 15
minutes to the light range (25–50).
Conclusions
Despite achieving a sustained therapeutic plasma concen-
tration of betamethasone, pain perception was
significantly increased in the immediate postoperative
period for the patients treated preoperatively with
Celestone Soluspan IM relative to placebo treated control
subjects in this triple blind randomized study. These
results indicate that anti-inflammatory steroids may be
useful in certain procedures, but are not uniformly effec-
tive in laparoscopic procedures with different patient
populations. Although not a controlled part of this study,
the confounding variables of extra intraoperative analge-
sics, type of laparoscopic operation, and postoperative
analgesics were also evaluated for impact on average post-
operative pain. The most significant effect was postopera-
tive opioid dose. Intraoperative administration of
ketorolac significantly reduced early pain scores and the
Plotted are the mean pain VAS scores (+ S.E.M. error bar) at survey times as in Figure 1 Figure 2
Plotted are the mean pain VAS scores (+ S.E.M. error bar) at survey times as in Figure 1. Repeated measures ANOVA as indi-
cated for all the other patients (shaded bar) compared to the patients with intraoperative prophylactic treatment with Ketoro-
lac (solid bar). Number of subjects interviewed at each time point is indicated above each set of bars. Number lower than 
enrolled reflects unresponsive subjects at early postoperative times and subjects discharged early for later time points. 
Repeated measures ANOVA showed a significant, within subject, effect of time (F = 13.776 (with Huynh-Feldt correction) ; P = 
0.009) but the interaction between time and treatment approached significance (F = 2.150; P = 0.06).
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Plotted are the mean pain VAS scores (+ S.E.M. error bar) with survey times as in Figure 1 Figure 3
Plotted are the mean pain VAS scores (+ S.E.M. error bar) with survey times as in Figure 1. Repeated measures ANOVA as 
indicated for patients undergoing tubal ligation (shaded bar) compared to the patients having diagnostic laparoscopy (solid bar). 
Number of subjects interviewed at each time point is indicated above each set of bars. Number lower than enrolled reflects 
unresponsive subjects at early postoperative times and subjects discharged early for later time points. Repeated measures 
ANOVA showed a significant, within subject, effect of time (F = 20.096 (with Huynh-Feldt correction) ; P = 0.009) but interac-
tion between time and treatment were not significant (F = 1.086; P = 0.37).
Table 2: Test Of Treatment Effects On Average Pain During The 2 Hour Postoperative Period
Treatment Pairs Adjusted Means Standard Error 95% Confidence 
Interval
Partial P Value
P (N = 35) 30 4 23 – 38 0.056
BM (N = 31) 40 4 33 – 47
Ketorolac (N = 17) 29 5 20 – 38 0.027
Other (N = 49) 41 3 36 – 47
Diagnostic (N = 29) 32 3 26 – 39 0.275
Tubal (N = 37) 38 4 30 – 46
Means are adjusted by an average opioid dose of 2.9 during the 2 hour postoperative period.
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requirement for postoperative pain relief drugs. Extra
intraoperative fentanyl was associated with an insignifi-
cant reduction, both in pain scores at the 2 hour time
point and in postoperative pain relief drugs.
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